Lunaphore raised CHF 23M in a Series C funding round
Our portfolio company, LUNAPHORE, a Swiss life-sciences company developing innovative next-generation equipment for cancer research and tissue diagnostics, raised CHF 23M in a Series C funding round.
The round was led by global healthcare company PHC Holding Corporation that owns Epredia, a leading provider of comprehensive solution for precision cancer diagnostics. Alpana Ventures and other co-investors participated in this financing round.
LUNAPHORE will invest the proceeds in market and product expansion.
Alpana congratulates LUNAPHORE’s team for this achievement.